Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Up 584.4% in June

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totaling 59,293 shares, a growth of 584.4% from the May 31st total of 8,663 shares. Based on an average daily volume of 412,091 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the shares of the company are short sold.

Fresenius SE & Co. Stock Performance

Shares of OTCMKTS:FSNUY traded down $0.07 during trading on Friday, hitting $11.40. 18,354 shares of the company traded hands, compared to its average volume of 123,447. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.41. The business’s fifty day moving average is $11.54 and its 200-day moving average is $13.17. The stock has a market capitalization of $25.68 billion, a price-to-earnings ratio of 15.20 and a beta of 0.64. Fresenius SE & Co. has a one year low of $10.33 and a one year high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.09% and a net margin of 6.55%.The company had revenue of $6.75 billion during the quarter, compared to the consensus estimate of $6.79 billion. As a group, equities analysts predict that Fresenius SE & Co. will post 1.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Fresenius SE & Co. currently has an average rating of “Buy”.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.